<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease that affects up to one third of the adult population of industrialized countries. The pathophysiological spectrum includes the following entities that are clinically and histologically distinct: hepatic steatosis and steatohepatitis; their subsequent evolution can lead to cirrhosis and hepatocellular carcinoma.The increase of the prevalence of NAFLD during the last decade is caused by the epidemiological and pathophysiological association with type II diabetes and obesity, NAFLD being present in about 70-80% of patients with type II diabetes mellitus. It has long been thought that the relationship between type II diabetes mellitus and NAFLD is unidirectional, fatty liver being secondary to insulin resistance and type II diabetes mellitus, but recent studies show that hepatic steatosis may precede insulin resistance and diabetes mellitus, thus demonstrating abidirectional causal relationship between these two disorders. Weight loss through diet andexercise is effective in preventing and treating NAFLD in diabetic patients; also, drugs that causeweight loss need to be evaluated. Both anti-diabetic medication and statins play an important vrole in the prevention and treatment of NAFLD.</p></abstract>

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease that affects up to one third of the adult population of industrialized countries. The pathophysiological spectrum includes the following entities that are clinically and histologically distinct: hepatic steatosis and steatohepatitis; their subsequent evolution can lead to cirrhosis and hepatocellular carcinoma.The increase of the prevalence of NAFLD during the last decade is caused by the epidemiological and pathophysiological association with type II diabetes and obesity, NAFLD being present in about 70-80% of patients with type II diabetes mellitus. It has long been thought that the relationship between type II diabetes mellitus and NAFLD is unidirectional, fatty liver being secondary to insulin resistance and type II diabetes mellitus, but recent studies show that hepatic steatosis may precede insulin resistance and diabetes mellitus, thus demonstrating abidirectional causal relationship between these two disorders. Weight loss through diet andexercise is effective in preventing and treating NAFLD in diabetic patients; also, drugs that causeweight loss need to be evaluated. Both anti-diabetic medication and statins play an important vrole in the prevention and treatment of NAFLD.

The Severity of Non-Alcoholic Fatty Liver in Type II Diabetes

Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"The Severity of Non-Alcoholic Fatty Liver in Type II Diabetes"}

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease that affects up to one third of the adult population of industrialized countries. The...

The Severity of Non-Alcoholic Fatty Liver in Type II Diabetes

Data publikacji: 28 mar 2019

Zakres stron: 37 - 42

DOI: https://doi.org/10.2478/inmed-2018-0044

Słowa kluczowe
nonalcoholic fatty liver disease, hepatic steatosis, steatohepatitis, cirrhosis, hepatocellular carcinoma, diabetes, insulin resistance

© 2018 Ovidiu Paul Calapod et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

The Severity of Non-Alcoholic Fatty Liver in Type II Diabetes

Data publikacji: 28 mar 2019

Zakres stron: 37 - 42

DOI: https://doi.org/10.2478/inmed-2018-0044

Słowa kluczowenonalcoholic fatty liver disease, hepatic steatosis, steatohepatitis, cirrhosis, hepatocellular carcinoma, diabetes, insulin resistance

© 2018 Ovidiu Paul Calapod et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Słowa kluczowe
nonalcoholic fatty liver disease, hepatic steatosis, steatohepatitis, cirrhosis, hepatocellular carcinoma, diabetes, insulin resistance